vTv Therapeutics (VTVT)
(Delayed Data from NSDQ)
$13.56 USD
+0.07 (0.52%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $13.74 +0.18 (1.33%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VTVT 13.56 +0.07(0.52%)
Will VTVT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VTVT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VTVT
Biotech Stock Roundup: BMY, GSK, BIIB's Q2 Results, VTVT Down on Setback
VTv Therapeutics (VTVT) Reports Q3 Loss, Lags Revenue Estimates
VTVT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Exact Sciences (EXAS) Reports Q3 Loss, Tops Revenue Estimates
Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Misses Revenue Estimates
Is Immunocore (IMCR) Stock Outpacing Its Medical Peers This Year?
Other News for VTVT
VTVT Stock Earnings: vTv Therapeutics Reported Results for Q2 2024
VTv Therapeutics: Q2 Earnings Snapshot
vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update
vTv Therapeutics GAAP EPS of -$0.81
vTv Therapeutics reports Q2 EPS (81c) vs. ($2.69) last year